Successful Treatment of Relapsed Chronic Lymphocytic Leukemia with Venetoclax in a Patient with Severe Chronic Kidney Disease

Hiroyuki Sugiura; Nobuo Sezaki; Tatsunori Ishikawa; Taiga Kuroi; Sachiyo Okamoto; Naho Nomura; Taro Masunari; Yukio Nakasako; Toru Kiguchi; Mitsune Tanimoto

doi:10.22541/au.164028087.79021919/v1

loading page

Successful Treatment of Relapsed Chronic Lymphocytic Leukemia with Venetoclax in a Patient with Severe Chronic Kidney Disease

Hiroyuki Sugiura,
Nobuo Sezaki,
Tatsunori Ishikawa,
Taiga Kuroi,
Sachiyo Okamoto,
Naho Nomura,
Taro Masunari,
Yukio Nakasako,
Toru Kiguchi,
Mitsune Tanimoto

Abstract

Venetoclax is a promising new drug for relapsed or refractory chronic lymphocytic leukemia (CLL). However, venetoclax use had not been reported in severe chronic kidney disease (CKD) patients. We report the first case of relapsed CLL in a severe CKD patient that was successfully treated with venetoclax.

14 Dec 2021Submitted to Clinical Case Reports

Show details

Hide details

14 Dec 2021Assigned to Editor

14 Dec 2021Submission Checks Completed

23 Dec 2021Reviewer(s) Assigned

16 Mar 2022Review(s) Completed, Editorial Evaluation Pending

25 Mar 2022Editorial Decision: Accept

Apr 2022Published in Clinical Case Reports volume 10 issue 4. 10.1002/ccr3.5735

Abstract

Peer review status:Published